PMID- 29954366 OWN - NLM STAT- MEDLINE DCOM- 20190624 LR - 20190624 IS - 1471-244X (Electronic) IS - 1471-244X (Linking) VI - 18 IP - 1 DP - 2018 Jun 28 TI - Subjective well-being, drug attitude, and changes in symptomatology in chronic schizophrenia patients starting treatment with new-generation antipsychotic medication. PG - 212 LID - 10.1186/s12888-018-1791-y [doi] LID - 212 AB - BACKGROUND: Non-adherence to medication remains a major challenge in the long-term management of patients with schizophrenia. Next to lack of insight into the illness, adverse effects of antipsychotic drugs, cognitive deficits, poor therapeutic alliance, reduced quality of life, missing social support, and negative attitudes toward medication are predictors of non-adherence. This study examined potential correlations between attitudes toward antipsychotic drug therapy, subjective well-being, and symptom change in patients with chronic schizophrenia. METHODS: 30 patients with schizophrenia starting monotherapy with a new-generation antipsychotic were included into the study. The Drug Attitude Inventory (DAI) and the Subjective Well-being under Neuroleptic Treatment Scale, short form (SWN-K), were administered after 2, 4, and 12 weeks of treatment. At the same points in time and at baseline, psychopathological symptoms were rated by means of the Positive and Negative Syndrome Scale (PANSS), and functioning was assessed by means of the Global Assessment of Functioning Scale (GAF). Antipsychotic induced side effects were evaluated by using the Udvalg for Kliniske Undersogelser (UKU) Side Effect Rating Scale. RESULTS: Study participants had a mean age of 37.5 +/- 9.7 years, baseline symptoms were mild. The PANSS total score improved significantly from baseline to weeks 4 (p = .003) and 12 (p = .001), respectively. Neither the DAI total score nor the SWN-K total score changed significantly over the course of time. The severity of symptoms was not correlated with drug attitude at any time point but was negatively correlated with wellbeing at weeks 2 (r = -.419, p = .021) and 4 (r = -.441, p = .015). There was no significant correlation between DAI and SWN-K total scores at any time point. CONCLUSIONS: Next to showing that the DAI and the SWN-K measure different aspects of subjective experiences during antipsychotic treatment these findings emphasize the use of both instruments to optimize adherence to medication. FAU - Widschwendter, Christian G AU - Widschwendter CG AD - Medical University Innsbruck, Department of Psychiatry,Psychotherapy, and Psychosomatics. Division of Psychiatry I, Anichstrasse 35, 6020, Innsbruck, Austria. christian.widschwendter@i-med.ac.at. FAU - Kemmler, Georg AU - Kemmler G AD - Medical University Innsbruck, Department of Psychiatry,Psychotherapy, and Psychosomatics. Division of Psychiatry I, Anichstrasse 35, 6020, Innsbruck, Austria. FAU - Rettenbacher, Maria A AU - Rettenbacher MA AD - Medical University Innsbruck, Department of Psychiatry,Psychotherapy, and Psychosomatics. Division of Psychiatry I, Anichstrasse 35, 6020, Innsbruck, Austria. FAU - Yalcin-Siedentopf, Nursen AU - Yalcin-Siedentopf N AD - Medical University Innsbruck, Department of Psychiatry,Psychotherapy, and Psychosomatics. Division of Psychiatry I, Anichstrasse 35, 6020, Innsbruck, Austria. FAU - Hofer, Alex AU - Hofer A AD - Medical University Innsbruck, Department of Psychiatry,Psychotherapy, and Psychosomatics. Division of Psychiatry I, Anichstrasse 35, 6020, Innsbruck, Austria. LA - eng PT - Journal Article DEP - 20180628 PL - England TA - BMC Psychiatry JT - BMC psychiatry JID - 100968559 RN - 0 (Antipsychotic Agents) SB - IM MH - Adult MH - Antipsychotic Agents/*therapeutic use MH - *Attitude MH - Chronic Disease MH - Female MH - Humans MH - Male MH - Middle Aged MH - Quality of Life/*psychology MH - Schizophrenia/diagnosis/*drug therapy MH - *Schizophrenic Psychology MH - Self Report/*standards MH - Treatment Outcome PMC - PMC6022409 COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: All procedures contributing to this work complied with the standards of the Ethics Committee of Medical University Innsbruck and were conducted according to Good Clinical Practice standards on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. CONSENT FOR PUBLICATION: No patient identifiable information has been reported. COMPETING INTERESTS: Christian Widschwendter, Georg Kemmler, and Nursen Yalcin-Siedentopf have no actual or potential conflict of interest. Maria A. Rettenbacher is member of a advisory board of Eli Lilly and has received speaker's or consultancy fees from Eli Lilly. Alex Hofer has received a research grant from Janssen-Cilag. He has received speaker's or consultancy fees from Bristol-Myers Squibb, Janssen-Cilag and Lundbeck as well as reimbursements for travel and meeting expenses from Janssen-Cilag and Lundbeck. PUBLISHER'S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. EDAT- 2018/06/30 06:00 MHDA- 2019/06/25 06:00 PMCR- 2018/06/28 CRDT- 2018/06/30 06:00 PHST- 2018/01/25 00:00 [received] PHST- 2018/06/12 00:00 [accepted] PHST- 2018/06/30 06:00 [entrez] PHST- 2018/06/30 06:00 [pubmed] PHST- 2019/06/25 06:00 [medline] PHST- 2018/06/28 00:00 [pmc-release] AID - 10.1186/s12888-018-1791-y [pii] AID - 1791 [pii] AID - 10.1186/s12888-018-1791-y [doi] PST - epublish SO - BMC Psychiatry. 2018 Jun 28;18(1):212. doi: 10.1186/s12888-018-1791-y.